Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress

Recruiting now

Conditions studied: Li-Fraumeni Syndrome, TP53 Gene Mutation, Hereditary Cancer Syndrome, Clonal Hematopoiesis, Mosaicism

In brief

The purpose of this research study is to learn more about variants in the TP53 gene both associated with Li-Fraumeni Syndrome (LFS), a hereditary cancer risk condition, and TP53 variants found in the blood for other reasons (e.g. ACE/CHIP and mosaicism).

Key facts

Study ID

NCT04541654

Run by

Dana-Farber Cancer Institute

People needed

1500

Starts

2020-09-15

Expected to finish

2032-12-31

Last updated by the study team

2026-03-27

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Individuals with a TP53 pathogenic or likely pathogenic variant identified in blood or saliva,
• Individuals with variants of uncertain significance in TP53 may be eligible at the PI's discretion,
• Blood relatives of individuals with a TP53 variant, who may be presumed obligate carriers or healthy controls,
• Individuals who meet Classic or Chompret LFS criteria whether or not they have a TP53 gene variant,
• Individuals may enroll their deceased relatives in the study.
• Individuals with a known TP53 variant that is not LFS, but rather ACE, CHIP, or mosaicism.
• Individuals participating in other LFS studies can still enroll in LiFT UP. Investigators may be collaborators.

You may not qualify if…

• Individuals who decline to sign consent
• Individuals who are unable to give consent or assent and are without a designated healthcare proxy

Where it is running

• Boston Children's Hospital — Boston, Massachusetts, United States (enrolling)
• Brigham and Women's Hospital — Boston, Massachusetts, United States (enrolling)
• Judy E. Garber — Boston, Massachusetts, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.